BioPharma Dive January 9, 2026
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.
Today, a brief rundown of news from Insmed and Johnson & Johnson, as well as updates from Madrigal Pharmaceuticals, Moonlake Immunotherapeutics, Eli Lilly and Lexeo Therapeutics that you may have missed.
Insmed said that Brinsupri, its recently approved drug for a chronic lung condition, generated close to $145 million in sales in its first full quarter on the market. Brinsupri is used to treat bronchiectasis not caused by cystic fibrosis and widely expected by Wall Street analysts to generate billions in sales. Still, the numbers announced Friday more than doubled...
Today's Sponsors
Today's Sponsor